RxDoctor Payments Data
★ My doctorsLook up a doctor →

Lewis Lane

Psychiatry · Dana Point, CANPI 1053452573

Payments from drug & device makers

$2,290in general payments, 2019–2025

Across 228 payments — averaging $10.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$354
  • Takeda Pharmaceuticals U.S.A., Inc.$271
  • Sunovion Pharmaceuticals Inc.$83
  • E.r. Squibb & Sons, L.L.C.$45
  • Lundbeck LLC$33
  • plus $53 from 4 others

What the payments were for

  • Food & beverage$2,290100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)135$1,450
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)38$354
Takeda Pharmaceuticals U.S.A., Inc.36$271
Sunovion Pharmaceuticals Inc.10$83
E.r. Squibb & Sons, L.L.C.3$45
Lundbeck LLC2$33
Alkermes, Inc.1$13
Vanda Pharmaceuticals Inc.1$13
Tris Pharma Inc1$13
Avanir Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,290 in reported general payments places this provider in the 80th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate11$18,667
RexultiBrexpiprazole12$17,756
AuvelityDextromethorphan Hbr/Bupropion14$15,172
Adderall XrDextroamphetamine/Amphetamine36$9,569
SaphrisAsenapine Maleate11$7,669
AdderallDextroamphetamine/Amphetamine14$4,482
Bupropion XlBupropion Hcl224$4,368
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine67$3,076
Aripiprazole41$3,050
Desvenlafaxine Succinate ErDesvenlafaxine Succinate29$2,092
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine53$1,558
Clonazepam168$1,108
Lorazepam106$1,100
Quetiapine Fumarate76$927
Trazodone Hcl95$889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$354$18,66711 claims
AbbVieSaphris$1,450$7,66911 claims
Takeda Pharmaceuticals U.S.A., Inc.Adderall$271$4,48214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Dana Point

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →